Comcast Drops Bally Sports Channels, Stops Broadcast of MLB Team Games 
Monster Beverage Sees Robust Growth with an 11.8% Revenue Surge 
Tesla Drivers Get $4k Off 2024 Chevy Blazer EV; Costco Auto Slashes Prices on New EVs 
2025 Sees SK hynix's HBM Chips Fully Booked Amidst AI Surge 
Mercedes-Benz Financial Appoints Korean Unit’s CEO 
Hyundai Motor Scales Up Hydrogen EV Truck Business in the US 
Sony Pictures, Apollo Looking to Jointly Acquire Paramount, Propose $26 Billion Cash Deal 
Biden Administration Set to Finalize Stricter EV Tax Credit Rules 
Arby’s Unveils New Menu Additions Plus Beyoncé-Inspired Chardonnay-Infused Sauce 
China set to blast off to the far side of the Moon – here’s what it could discover 
Dongfeng Unveils High-Power Tesla Cybertruck Rival, Eyes Production in Italy 
Kakao Enhances AI Focus, Merges Kakao Brain Into Core Operations 
Kakao Gets Approval to Acquire SM Entertainment Controlling Stake 
Taylor Swift, Justin Bieber, Billie Eilish Universal Music Label Signs New Deal With TikTok, Ending Dispute 
Samsung Chief Lee Jae-yong Wraps Up Europe Visit, Includes Vatican and Zeiss 
Major Victory for Bayer's Monsanto as Appeals Court Overturns $185 Million Award in Chemical Exposure Case 
Electric air taxis are on the way – quiet eVTOLs may be flying passengers as early as 2025 
IRVINE, Calif., Sept. 07, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s” or the “Company”) (NYSE:RDY). Investors who purchased or otherwise acquired shares between June 17, 2015 and August 10, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the October 24, 2017 lead plaintiff motion deadline.
If you purchased Dr. Reddy’s shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Dr. Reddy’s made false and/or misleading statements, and/or failed to disclose, that the Company lacked an effective corporate quality system; and thus, its public statements were materially false and misleading at all relevant times. On August 10, 2017, Dr. Reddy’s disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. When this news was announced, shares of Dr. Reddy’s lowered in value materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
